Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study The 6-month discontinuation rates of tamoxifen ...

An enzyme called CYP2D6 converts tamoxifen to its active form, and some research has suggested that if the enzyme is blocked, tamoxifen won’t be as effective, thus causing patients to recur sooner ...

Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, ...

Cytochrome P450 2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)) is involved in the phase I metabolism of approximately one-quarter of the most commonly prescribed medications, ...

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, ...

December 10, 2010 (San Antonio, Texas) — New analyses of data from 2 large trials have found no association between the CYP2D6 genotype and the effectiveness of tamoxifen in preventing breast cancer ...

Recent advances in oligonucleotide microarray technology (“gene chips”) permit rapid screening for DNA sequence variation. The CYP2D6 gene encodes debrisoquine hydroxylase, which metabolizes the ...

Gentris Corporation has announced the availability of Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene (CYP2D6). CYP2D6 affects the metabolism of a large number of compounds, ...

(A) Transgene structures for the expression of the exogenous FLAG-tagged CYP2D6 protein or the IRES-based co-expression of the human hepatic CYP2D6 and GFP proteins. (B) Phase contrast images of the ...

Aim We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & Methods Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for ...